CalciMedica, Inc.
CALC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -49.59 | -0.09 | -0.15 | 0.08 |
| FCF Yield | -0.01% | -27.82% | -18.12% | -11.01% |
| EV / EBITDA | -8,264.51 | -4.73 | -5.03 | -8.77 |
| Quality | ||||
| ROIC | -50.02% | -42.43% | -31.10% | -38.31% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.61 | 1.12 | 0.97 | 1.17 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 28.30% | -36.59% | 1.75% | 69.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.97 | -0.46 | 0.86 | 1.87 |
| Interest Coverage | 17.23 | -20.44 | -14.53 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -12,291.43 | -12,096.00 | -5,994.00 |